bis(4-amino-2-chlorophenyl) disulfide | 729-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis(4-amino-2-chlorophenyl) disulfide
• 英文别名: 4,4'-disulfanediylbis(3-chloroaniline)；4,4'-Dithio-di-(3-chloranilin)；2,2'-Dichlor-4,4'-diamino-diphenyldisulfid；Bis-(4-amino-2-chlor-phenyl)-disulfid；4,4'-diamino-2,2'-dichlorodiphenyldisulphide；4-[(4-amino-2-chlorophenyl)disulfanyl]-3-chloroaniline
• CAS: 729-41-9
• 化学式: C₁₂H₁₀Cl₂N₂S₂
• 分子量: 317.263
• InChiKey: DQRYQIULVDVESM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  bis(4-amino-2-chlorophenyl) disulfide 以72%的产率得到双(2-氯-4-氟苯基)二硫化物
  参考文献：
  名称：

  2-氯-4-氟-5-硝基苯磺酰氯的新合成

  摘要：

  2-Chloro-4-fluoro-5-nitrobenzosulfonyl chloride (4) 可用于合成关键中间体 5-amino-2-chloro-4-fl~orophenylthioacetate~，进而用于制备农药例如除草剂j7uthiacet-methyL2 Kojima等人通过4-氯-2-氟硝基苯与氯磺酸的氯磺化以78%的收率制备了4。由于 4-氯-2-氟硝基苯非常昂贵且难以制备，因此寻找了 4 的替代途径。因此，我们报告了使用 Schiemann 反应从双（4-氨基-2-氯苯基）二硫化物 (1) 合成 4 、氧氯化和硝化如Scheme所示。起始原料1先前已由3,4-二氯硝基苯制备。如Scheme所示，双(2-氯-4-氟苯基)二硫化物(2)通过典型的Schiemann反应(步骤a)制备，包括在酸性条件下用亚硝酸钠重氮化(20%硫酸是该反应的优化介质)，用四氟硼酸和沉淀的四氟硼酸重氮的热解。1

  DOI：

  10.1080/00304940509354987
• 作为产物：
  描述：

  1,2-bis(2-chloro-4-nitrophenyl)disulfane 在 乙醇 、 一水合肼 作用下， 生成 bis(4-amino-2-chlorophenyl) disulfide
  参考文献：
  名称：

  用乙氧基亚甲基丙二酸酯法合成一些4-喹啉醇和4-氯喹啉。

  摘要：

  DOI：

  10.1021/ja01211a038

文献信息

• Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
  申请人：AVENTIS PHARMA S.A.

  公开号：US20040248884A1

  公开（公告）日：2004-12-09

  The present invention relates to a cyclic urea compound of formula I: 1 as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

  本发明涉及一种如下式的环脲化合物： 1 如本文所定义。该发明还涉及其制备方法，包括它的药物组合物以及其作为蛋白激酶抑制剂的药用，因此，它对于预防或治疗能够通过抑制蛋白激酶活性而调节的生理紊乱是有用的，比如固体肿瘤。
• Pyridyl and quinoline derivatives
  申请人：Leo Pharmaceutical Products Ltd.

  公开号：US04826987A1

  公开（公告）日：1989-05-02

  The present invention relates to compounds of formula I ##STR1## in which formula I X stands for O, S, ##STR2## R.sub.1 and R.sub.2 which can be the same or different stand for hydrogen, straight or branched, saturated or unsaturated, unsubstituted or substituted C.sub.1 -C.sub.8 -alkyl, or for ar-C.sub.1 -C.sub.4 -alkyl, aryl and ar being unsubstituted or substituted phenyl; R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are the same or different and stand for hydrogen, halogen, pseudo halogen, cyano, nitro, amino, carboxy, hydroxy, alkyl, alkoxy; or R.sub.5 and R.sub.6 form an aromatic ring which is fused to the pyridyl ring, and which aromatic ring may substituted; provided that R.sub.1 and R.sub.2 cannot be hydrogen at the same time, and provided that when R.sub.5 and R.sub.6 both are chlorine and R.sub.1 is hydrogen, then R.sub.2 cannot be n-propyl; and salts and bioreversible derivatives thereof. The compounds of formula I are useful in the human and veterinary therapy, as they exert specific 5-lipoxygenase inhibition.

  本发明涉及以下式的化合物##STR1## 在该式中，X代表O、S、##STR2## R.sub.1和R.sub.2可以相同也可以不同，代表氢、直链或支链、饱和或不饱和、未取代或取代的C.sub.1-C.sub.8-烷基，或者代表ar-C.sub.1-C.sub.4-烷基，aryl和ar代表未取代或取代的苯基；R.sub.3、R.sub.4、R.sub.5和R.sub.6可以相同也可以不同，代表氢、卤素、伪卤素、氰基、硝基、氨基、羧基、羟基、烷基、烷氧基；或者R.sub.5和R.sub.6形成与吡啶环融合的芳香环，该芳香环可以被取代；但是R.sub.1和R.sub.2不能同时是氢，当R.sub.5和R.sub.6都是氯且R.sub.1是氢时，R.sub.2不能是正丙基；以及其盐和生物可逆衍生物。式I的化合物在人类和兽医疗法中是有用的，因为它们具有特异的5-脂氧酶抑制作用。
• 2-quinolinyl methoxy compounds, medical uses and intermediates therefor
  申请人：Leo Pharmaceutical Products Ltd.

  公开号：US05157039A1

  公开（公告）日：1992-10-20

  The present invention relates to compounds of formula ##STR1## in which formula I X stands for O, S, ##STR2## R.sub.1 and R.sub.2 which can be the same or different stand for hydrogen, straight or branched, saturated or unsaturated, unsubstituted or substituted C.sub.1- C.sub.8 -alkyl, aryl or for ar-C.sub.1 -C.sub.4 -alkyl, aryl and ar being unsubstituted or substituted phenyl; R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are the same or different and stand for hydrogen, halogen, pseudo halogen, cyano, nitro, amino, carboxy, hydroxy, alkyl, alkoxy; or R.sub.5 and R.sub.6 form an aromatic ring which is fused to the pyridyl ring, and which aromatic ring may substituted; provided that R.sub.1 and R.sub.2 cannot be hydrogen at the same time, and provided that when R.sub.5 and R.sub.6 both are chlorine and R.sub.1 is hydrogen, then R.sub.2 cannot be n-propyl; and salts and bioreversible derivatives thereof. The compounds of formula I are useful in the human and veterinary therapy, as they exert specific 5-lipoxygenase inhibition.

  本发明涉及以下结构的化合物：##STR1## 其中式中 X 代表 O、S、##STR2## R.sub.1 和 R.sub.2 可以相同也可以不同，代表氢、直链或支链、饱和或不饱和、未取代或取代的 C.sub.1-C.sub.8-烷基、芳基或 ar-C.sub.1-C.sub.4-烷基，芳基和 ar 均为未取代或取代的苯基；R.sub.3、R.sub.4、R.sub.5 和 R.sub.6 可以相同也可以不同，代表氢、卤素、伪卤素、氰基、硝基、氨基、羧基、羟基、烷基、烷氧基；或者 R.sub.5 和 R.sub.6 形成与吡啶环融合的芳香环，该芳香环可以被取代；但要求 R.sub.1 和 R.sub.2 不能同时为氢，当 R.sub.5 和 R.sub.6 都是氯且 R.sub.1 是氢时，R.sub.2 不能是 n-丙基；以及其盐和生物可逆衍生物。式中的化合物在人类和兽医治疗中具有特异的5-脂氧酶抑制作用。
• Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
  申请人：PATEK Marcel

  公开号：US20080108654A1

  公开（公告）日：2008-05-08

  The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

  本公开涉及一种公式I的环状脲化合物，如此定义，以及其制备过程，包含该化合物的制药组合物和其作为蛋白激酶抑制剂的药物用途。因此，公式I的化合物对于预防或治疗能够通过抑制蛋白激酶活性调节的生理紊乱，如实体肿瘤，是有用的。
• Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
  申请人：Aventis Pharma SA

  公开号：US07354933B2

  公开（公告）日：2008-04-08

  The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

  本发明涉及一种公式I的环状脲化合物，如本文所定义。该发明还涉及其制备过程、包含它的药物组成物及其作为蛋白激酶抑制剂的药物用途。因此，它可用于预防或治疗能够通过抑制蛋白激酶活性来调节的生理紊乱，如实体肿瘤。